Predilife SA Raises €900k Convertible Bonds, Gains FDA Nod on DenSeeRisk
Predilife SA raises €900k via 8.5% convertible bonds, secures FDA approval for DenSeeRisk, and validates its MammoRisk breast‑cancer platform—boosting biotech growth.
2 minutes to read